CVT Hopes MERLIN Is Magic: Can Outcomes Trial Reverse Ranexa’s Fortune?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Large outcomes studies "will be the wave of the future for many products, not just cardiovascular products," CV Therapeutics CEO Louis Lange predicted during a Feb. 8 earnings call.
You may also be interested in...
CV Therapeutics’ Pre-"Approvable" Letter To FDA’s Temple
Excerpts from an Oct. 20, 2003 letter to Office of Drug Evaluation I Director Robert Temple. CV Therapeutics CEO Robert Lange and VP-Clinical R&D Andrew Wolff proposed a risk management program (ultimately not instituted upon approval) and downplayed QT concerns regarding Ranexa. FDA issued an "approvable" letter ten days later.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.